Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Embrace

- PMLiVE

J&J gets FDA panel backing for canagliflozin

Moves ahead of BMS/AZ’s Forxiga in race for US approval as first in new class of diabetes drug

- PMLiVE

FDA lowers recommended dose for sleeping pills

Says insomnia drugs like Ambien could impair ability to drive in morning

- PMLiVE

FDA releases guidance on how to prevent abuse of opioid painkillers

Explains to companies best ways to make tamper-resistant drugs

Gary Nabel to lead Sanofi’s strategy council

Pharma firm’s chief scientific officer replaces Richard Klausner

Sanofi reception

Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

Hanspeter Spek to retire from Sanofi

President of global operations will step down after 18 years at the pharma company

- PMLiVE

Sanofi boosts animal health business with Dosch acquisition

Opens door to €350m market for company’s Merial division

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

Sanofi reception

Blow for Sanofi as EMA turns down cholesterol drug Kynamro

Points to safety concerns related to liver toxicity and cardiovascular events

- PMLiVE

Sanofi picks corporate voice for new blogging venture

Pharma company's US arm goes beyond discussing diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links